• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 7:36:20 AM ET
    $LOAC
    Business Services
    Finance
    Get the next $LOAC alert in real time by email
    SC 13G/A 1 loaca1_21621.htm OXFORD ASSET MANAGEMENT LLP loaca1_21621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Longevity Acquisition Corporation
    (Name of Issuer)
    Ordinary shares, no par value
    (Title of Class of Securities)
    G56372132
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: G56372132
           
    1
    NAME OF REPORTING PERSON
    OxFORD ASSET MANAGEMENT LLP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    UNITED KINGDOM
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: G56372132
    ITEM 1(a). NAME OF ISSUER:
    Longevity Acquisition Corporation
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    Yongda International Tower No. 2277

    Longyang Road, Pudong District, Shanghai

    Peoples Republic of China
    ITEM 2(a). NAME OF PERSON FILING:
    This Amendment No.1 amends and supplements the statement on Schedule 13G filed with the Securities and Exchange Commission on February 13, 2020 (the "Original Schedule 13G") and is filed on behalf of OxFORD Asset Management LLP ("OxFORD").

    This Statement relates to Shares (as defined herein) held for the account of OxAM Quant Fund Limited, a Cayman Islands exempted company ("OxAM"). OxFORD serves as investment adviser to OxAM. In such capacity, OxFORD may be deemed to exercise the voting and dispositive power over the Shares held for the account of OxAM.
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    OxAM House, 6 George Street, Oxford, United Kingdom, OX1 2BW
    ITEM 2(c). CITIZENSHIP:
    OxFORD is a limited liability partnership incorporated in England and Wales.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Ordinary shares, no par value
    ITEM 2(e). CUSIP NUMBER:
    G56372132
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    Item 4(a) of the Original Schedule 13G is hereby amended as follows:

    As of December 31st, 2020, the Reporting Person may be deemed the beneficial owner of 0
    Shares held for the account of OxAM.
    (b) Percent of class:
    Item 4(b) of the Original Schedule 13G is hereby amended as follows:

    As of December 31st, 2020, the Reporting Person may be deemed the beneficial owner of 0.00% of Shares outstanding
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    0
    (ii) shared power to vote or to direct the vote:
    0
    (iii) sole power to dispose or direct the disposition of:
    0
    (iv) shared power to dispose or to direct the disposition of:
    0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    See disclosure in Items 2 and 4 hereof. OxAM has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Person.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    This Item 7 is not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    This Item 8 is not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    This Item 9 is not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: G56372132
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 16 2021
    OxFORD ASSET MANAGEMENT LLP
    By:
    /s/ Mark Garfield
    Name:
    Mark Garfield
    Title:
    Chief Compliance Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $LOAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LOAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LOAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC). 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’ Warrants of Longevity assumed by 4D pharma in the Merger are currently expected to begin trading on Nasdaq under the ticker symbol ‘LBPSW’ tomorrow, Tuesday, March 23, 2021. Lo

    3/22/21 3:00:00 AM ET
    $LOAC
    Business Services
    Finance

    Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders

    NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its special meeting of shareholders, which was held on March 17, 2021. At the special meeting, shareholders of the Company approved the merger, including a certain agreement and plan of merger, dated as of October 21, 2020, by and among 4d pharma plc, the Company and Dolphin Merger Sub Limited, and the related agreements and transactions contemplated thereby. About LOAC LOAC is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of

    3/18/21 8:00:00 AM ET
    $LOAC
    Business Services
    Finance

    4D Pharma to Present at Upcoming Investor Conferences in March

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences: Chardan's Virtual 3rd Annual Microbiome Medicines Summit: Monday March 8, 2021 at 11:45 am ET (16:45 GMT). H.C. Wainwright Global Life Sciences Conference: Available on-demand starting Tuesday, March 9, 2021 at 7:00 am ET (12:00 GMT). Oppenheimer’s 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 8:40 am ET (12:40 GMT). About 4D pharma Founded in February 2014, 4D pharma is a w

    3/3/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    SEC Filings

    View All

    SEC Form EFFECT filed by Longevity Acquisition Corporation

    EFFECT - Longevity Acquisition Corp (0001743858) (Filer)

    4/7/21 12:15:42 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form 15-15D filed by Longevity Acquisition Corporation

    15-15D - Longevity Acquisition Corp (0001743858) (Filer)

    4/1/21 1:05:04 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form POS AM filed by Longevity Acquisition Corporation

    POS AM - Longevity Acquisition Corp (0001743858) (Filer)

    3/31/21 1:21:13 PM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Leadership Updates

    Live Leadership Updates

    View All

    4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. “John will be an important addition to 4D pharma’s management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expert

    3/1/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 3:16:03 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 7:36:20 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/12/21 4:21:17 PM ET
    $LOAC
    Business Services
    Finance